THE WHAT? Hims & Hers unveiled a compounded weight-loss pill with a headline-grabbing US$49-a-month introductory price, triggering industry buzz but a sell-off in its shares.
THE DETAILS The digital health company said it plans to offer a discounted compounded version of Novo Nordisk’s Wegovy, undercutting branded GLP-1 drugs in the booming weight-loss market. While the announcement initially sent Hims shares up 14% at the open, the stock reversed course to close down 4%, with further losses after FDA Commissioner Martin Makary warned of “swift action” against companies mass-marketing illegal copycat drugs. Analysts noted the US$49 price applies only to the first month, rising to US$99 thereafter under longer plans. Hims’ stock has been volatile, having lost around 60% since mid-October despite nearly tripling over the past two years.
THE WHY? Investors remain cautious as regulatory scrutiny intensifies around compounded GLP-1 drugs and questions persist over the sustainability and legality of ultra-low pricing strategies.
Source: Reuters
date: 2026-02-09 06:05:00